Major human airways diseases, including CORD and CF, exhibit obstruction of airway lumens with mucus. This tPPG is based on the premise that novel biophysical and biochemical hypotheses are required to adequately describe airway mucus transport in health, predict how and when the system fails in disease, and invent novel therapies to treat these ainways diseases. We hypothesize that effective and specific therapies will require dual therapeutic activities: 1) a mucus """"""""hydrating"""""""" activity;and 2) a """"""""mucolytic"""""""" activity, i.e., an agent that wil decrease mucus cohesion and/or adhesion. This tPPG application presents three Projects and five Cores designed to provide the scientific basis, biomarkers, and tests of novel therapies to treat muco-obstructive diseases. The Administrative Core (Core A) will oversee the fusion of physical and biological sciences that underpins our attack on this problem, key pre-clinical models for testing novel therapeutic strategies, and clinical trials to accomplish our overarching goals of: 1) testing in human subjects novel delivery devices and single/combination therapies focused on airway re-hydration;and 2) developing a novel mucolytic platform and testing inhibitors of mucin gene transcription. Thus, Core A will oversee three Projects: 1) """"""""The Biophysics of Mucus Hydration and Adhesion/Cohesion"""""""" -Michael Rubenstein, Ph.D., P.I.;2) """"""""Mucus Obstructed Mice for Biomarker and Drug Development"""""""" - Richard Boucher, M.D., P.I.;3) """"""""Targeting Defective Mucus Clearance in COPD"""""""" - Scott Donaldson, M.D., P.I. Core A will oversee four Cores: 1) Core B (the Biostatistics and Data Management Core);2) Core C (the Mucus Core), which will provide state-of-the-art measurements of mucin concentration/biophysical properties;3) Core D [the Pharmacokinetics/Pharmacodynamics (PK/PD) Core], which will provide a range of PK/PD methodologies for testing activities of topical muco-active agents;and 4) Core E (the Compound/Combination Selection Core) - which will provide in vitro and animal model screens. In sum, the activities of the tPPG are integrated to provide the scientific bases to initiate clinical studies of novel delivery devices, to test combinations of hydrating agents, and to develop a new mucolytic drug for therapy of COPD.

Public Health Relevance

Our overarching hypothesis is that a relatively dehydrated mucus layer, reflecting either depletion of salt/water, and/or increased mucin secretion, or both, produces a failure of mucus transport, mucus adhesion, and an ensuing sequence that produces inflammation, bacterial infection, and airways remodeling in major human diseases, e.g., COPD and CF. This tPGG is designed develop novel therapies and devices for these diseases in both near-term and longer term time frames.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
3P01HL108808-02S1
Application #
8774753
Study Section
Special Emphasis Panel (ZHL1-CSR-Q (F1))
Program Officer
Banks-Schlegel, Susan P
Project Start
2012-06-15
Project End
2017-05-31
Budget Start
2013-12-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2014
Total Cost
$41,786
Indirect Cost
$14,295
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Abdullah, Lubna H; Coakley, Raymond; Webster, Megan J et al. (2018) Mucin Production and Hydration Responses to Mucopurulent Materials in Normal versus Cystic Fibrosis Airway Epithelia. Am J Respir Crit Care Med 197:481-491
Yu, Dongfang; Saini, Yogesh; Chen, Gang et al. (2018) Loss of ? Epithelial Sodium Channel Function in Meibomian Glands Produces Pseudohypoaldosteronism 1-Like Ocular Disease in Mice. Am J Pathol 188:95-110
Muhlebach, Marianne S; Hatch, Joseph E; Einarsson, Gisli G et al. (2018) Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur Respir J 52:
Livraghi-Butrico, Alessandra; Wilkinson, Kristen J; Volmer, Allison S et al. (2018) Lung disease phenotypes caused by overexpression of combinations of ?-, ?-, and ?-subunits of the epithelial sodium channel in mouse airways. Am J Physiol Lung Cell Mol Physiol 314:L318-L331
Chen, Gang; Volmer, Allison S; Wilkinson, Kristen J et al. (2018) Role of Spdef in the Regulation of Muc5b Expression in the Airways of Naive and Mucoobstructed Mice. Am J Respir Cell Mol Biol 59:383-396
Bennett, William D; Zeman, Kirby L; Laube, Beth L et al. (2018) Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis. J Aerosol Med Pulm Drug Deliv 31:204-211
Ge, Ting; Grest, Gary S; Rubinstein, Michael (2018) Nanorheology of Entangled Polymer Melts. Phys Rev Lett 120:057801
Ribeiro, Carla M P; Lubamba, Bob A (2017) Role of IRE1?/XBP-1 in Cystic Fibrosis Airway Inflammation. Int J Mol Sci 18:
Everaers, Ralf; Grosberg, Alexander Y; Rubinstein, Michael et al. (2017) Flory theory of randomly branched polymers. Soft Matter 13:1223-1234
Peters, Brandon L; Pike, Darin Q; Rubinstein, Michael et al. (2017) Polymers at Liquid/Vapor Interface. ACS Macro Lett 6:1191-1195

Showing the most recent 10 out of 76 publications